Axicabtagene ciloleucel (Yescarta®) (CAR-T)
Indication
00717a
Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.
00717b
For the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Fludarabine and cycloPHOSphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)
Indication
00608a
Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy with axicabtagene ciloleucel (Yescarta®) in adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.
00608b
Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy with axicabtagene ciloleucel (Yescarta®) in adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Brexucabtagene Autoleucel (Tecartus®) (CAR-T) B-cell ALL
Indication
00898a
For the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)
Fludarabine & cycloPHOSphamide Lymphodepletion for Brexucabtagene Autoleucel (Tecartus®) B-cell ALL
Indication
00899a
Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy brexucabtagene autoleucel (Tecartus®) in adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)
Ciltacabtagene Autoleucel (Carvykti®) Multiple Myeloma
Indication
00835a
For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.
00835b
For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.
Fludarabine and cycloPHOSphamide Lymphodepletion for Ciltacabtagene Autoleucel (Carvykti®) Multiple Myeloma Therapy
Indication
00836a
Lymphodepletion therapy regimen pre-treatment for CAR-T therapy with ciltacabtagene autoleucel (Carvykti®) in the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.
00836b
Lymphodepletion therapy regimen pre-treatment for CAR-T therapy with ciltacabtagene autoleucel (Carvykti®) in the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor,have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.
Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL and FL
Indication
00606a
Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy
00606b
Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Fludarabine & cycloPHOSphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL
Indication
00607a
Lymphodepleting chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients aged 18-25 years with B-cell ALL that is refractory, in relapse post-transplant or in second or later relapse
Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL and FL
Indication
00687a
Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
00687b
Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL
Indication
00686a
Treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse